title: Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
abstract: BACKGROUND
  To identify differences between the effects of calcitriol and the calcitriol analogue, maxacalcitol, on parathyroid hormone (PTH) and bone metabolisms, we conducted a randomized prospective multicentre study on patients on chronic haemodialysis.
  
  
  METHODS
  We randomly assigned 91 patients with secondary hyperparathyroidism [intact PTH (iPTH) > or =150 pg/ml] to have either calcitriol (47 patients) or maxacalcitol (44 patients) therapy, for 12 months after a 1 month control period. Serum electrolytes, bone alkaline phosphatase (bAP), iPTH, total PTH and PTH(1-84) (whole PTH) levels were measured periodically. The first end point was a serum iPTH of <150 pg/ml, the second was the iPTH levels obtained.
  
  
  RESULTS
  Treatment was discontinued for various reasons in nine patients in each group, but no serious side effects were observed in either group. The numbers of cases reaching the first end point were not significantly different between the two groups. Serum calcium concentration was significantly higher in the maxacalcitol than the calcitriol group during early treatment, but not at the end of treatment. Throughout the treatment period there were no significant differences between the two groups in serum iPTH, inorganic phosphate, the product of the serum calcium and inorganic phosphorus concentrations, bAP, or the ratio of whole PTH to total PTH minus whole PTH. Nor were the changes in these parameters significantly different between the two groups comparing the patients with moderate to severe hyperparathyroidism (basal iPTH > or =500 pg/ml).
  
  
  CONCLUSIONS
  Calcitriol and maxacalcitol are equally effective on PTH and bone metabolism.
authors.affiliation: Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. matuhiko@sc.itc.keio.ac.jp
authors.forename: Matsuhiko
authors.initials: M
authors.lastname: Hayashi
authors.forename: Yoshitsugu
authors.initials: Y
authors.lastname: Tsuchiya
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Itaya
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Takenaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Mamoru
authors.initials: M
authors.lastname: Yoshizawa
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Nakamura
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Monkawa
authors.forename: Atsuhiro
authors.initials: A
authors.lastname: Ichihara
mesh_terms: D000469:Alkaline Phosphatase / Q000378:metabolism; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D002117:Calcitriol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D002120:Calcium Channel Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011446:Prospective Studies; D006435:Renal Dialysis
chemical_list: D002120:Calcium Channel Agonists; D010281:Parathyroid Hormone; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002117:Calcitriol; C051883:maxacalcitol; D002118:Calcium